Menu
Close
Personalized Precision Treatment Support
Redefining treatments with AI-driven precision medicine
The M-Platform provides healthcare professionals with precise treatment recommendations. Harnessing AI and comprehensive biomedical data at a molecular level, medical avatars simulate treatments and patient-specific reactions to thousands of medications – matching patients with medicines that work on them. Accessible via local or remote servers, M supports the replication of over 13,500 treated diseases, initially focusing on lymphoma, melanoma, breast- and lung cancer.
m-platform
The M-platform uses pioneering technology to create personalized medical avatarspredicting patient responses to medications with extensive biomedical data. It offers scalable, AI-driven healthcare by modeling over 13,500 diseases, initially focusing on breast, lung, lymphoma, and melanoma cancers
Patient Biomarker Data
Mavatar Generation
Tailored Recommendations
.jpg)
Patient Biomarker Data
A medical professional uploads patient biomarker data to the M-platform, which compares it against an extensive genetic, proteomic, and transcriptomic database to create a comprehensive biological profile of the patient.
Mavatar Generation
The M-platform generates a medical avatar, a virtual representation that simulates the patient's biological processes and disease progression. It runs simulations on medical avatars with similar symptoms to test various treatment options and identifies the most effective therapies.
Tailored Recommendations
Based on these simulations, the platform provides real-time, personalized drug recommendations tailored to the patient's unique genetic and molecular profile
The M-platform generates a medical avatar, a virtual representation that simulates the patients biological processes and disease progression. It runs simulations on medical avatars with similar symptoms to test various treatment options and identifies the most effective therapies.
Pharma Development Partner
Mimer Platform
The Mimer platform helps pharma companies develop drugs faster and more effectively.